DLX4 and ovarian carcinoma: showed that DLX4 induced CD44 expression by stimulating interleukin (IL)-1β-mediated nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activity, thereby promoting peritoneal metastasis of ovarian cancer [35].